<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CCA3449A-E512-4E70-83E1-36F294C2D0AF"><gtr:id>CCA3449A-E512-4E70-83E1-36F294C2D0AF</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Nibbs</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/05D2CC8E-58CE-41FC-80DA-C3684C41F92E"><gtr:id>05D2CC8E-58CE-41FC-80DA-C3684C41F92E</gtr:id><gtr:firstName>Owen James</gtr:firstName><gtr:surname>Sansom</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900992"><gtr:id>06E9D151-F3C4-411A-A359-323C082CA5B7</gtr:id><gtr:title>An investigation of the pro-tumorigenic activity of the chemokine receptor CXCR2 using models of de novo tumorigenesis.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900992</gtr:grantReference><gtr:abstractText>In humans and animals, persistent inflammation of tissues can increase the likelihood of developing cancer. In addition, cancers induce inflammation to create an environment that helps support their development and progression. We are interested in understanding these links between cancer and inflammation at the level of individual molecules. Our research has focused on the migration of white blood cells into tissues from the blood, a key component of all inflammation. These cells normally provide protection from infection and help repair damaged tissue, but they also bring with them a host of molecules that inadvertently help support cancers. If we could understand how white blood cell migration occurs, we may be able to develop medicines that interfere with it. This is a relatively under-explored area of cancer biology, but could yield new medicines for treating cancer patients. Excitingly, we have found that a molecule called CXCR2, which is critical for the migration of white blood cells into tissues during inflammation, plays an indispensable role in assisting the development of cancers in the skin and colon of mice. The proposed work plans to build on these observations and aims to fully understand how and why CXCR2 has such profound pro-cancer activity. Significantly, medicines that block the function of CXCR2 are already under development and, using mouse models of cancer, we plan to test whether they have real therapeutic potential. We believe these studies will not only advance our understanding of the interactions between inflammation and cancer, but also have the potential to lead to the development of novel approaches to cancer treatment in humans.</gtr:abstractText><gtr:technicalSummary>Inflammation and tumorigenesis are intimately linked. Chronic inflammation increases the risk of developing many cancers, and tumours use inflammatory signals to establish supportive microenvironments. Pro-inflammatory molecules that contribute to these processes represent a relatively under-explored source of possible therapeutic targets. Chemokines and their receptors are of fundamental importance in orchestrating inflammatory responses, and we have recently discovered that the chemokine receptor CXCR2 plays a profound pro-tumorigenic role in mouse models of de novo tumorigenesis in both the skin and the intestine. These observations, in combination with a wealth of data generated by us and others, have lead us to hypothesise that CXCR2 makes a major contribution to both inflammation-driven and spontaneous tumorigenesis in multiple tissues, and that this is because of its ability to recruit leukocytes, particularly neutrophils, into these tissues and the tumours developing within them. We will use genetically-modified mice and models of cutaneous and intestinal tumorigenesis to rigorously test this hypothesis. In addition, we will perform proof-of-concept studies in mice exploring CXCR2 inhibition as an anti-cancer therapy. Collectively, we believe these studies will advance our understanding of the links between inflammation, chemokines and cancer. Moreover, with high expression of CXCR2 ligands common in many human cancers, and CXCR2 antagonists already in clinical trials, this work could lead to the rapid development of novel cancer therapies worthy of consideration for treating human disease.</gtr:technicalSummary><gtr:fund><gtr:end>2012-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>404388</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>NCRI 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AEA1D716-DA75-4A23-BABF-458FA7D1C979</gtr:id><gtr:impact>Research findings communicated and stimulated discussions.

After presentation, I was contacted by several researchers seeking more information and the possibility of collaboration.</gtr:impact><gtr:outcomeId>54649a7377f297.06969441</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alumni Networking</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>00575EBD-49CC-4950-B5AB-D8E99015B5BD</gtr:id><gtr:impact>Establishment of a Facebook networking site for alumni of Glasgow University's Immunology BSc course.

~300 alumni connected via social media and a site to advertise and disseminate job and postgraduate opportunities in Glasgow, UK, and internationally. Source of individuals to provide advice, and act as contacts, for current final year students.</gtr:impact><gtr:outcomeId>fxZJvqHju7r</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glasgow University Open Days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8B25DEE0-41FD-46A4-8A54-18AF3A8FC4FB</gtr:id><gtr:impact>Promotion of Glasgow University's research and teaching to ~100 prospective students and their parents.

Increase in interest in studying Immunology at Glasgow University.</gtr:impact><gtr:outcomeId>PS3ashQV95H</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.gla.ac.uk/about/visit/opendays/</gtr:url><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EACR/IACR 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>16DC168B-94AA-42BC-B71E-2041CA6DE5D0</gtr:id><gtr:impact>Dissemination of research findings and stimulation of discussion and future work/collaboration.

Increased international research profile and established new collaborative links.</gtr:impact><gtr:outcomeId>546499053b00c7.11134738</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BICR conference 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C8882E73-620C-4F1A-86B8-DFC5C76C55AB</gtr:id><gtr:impact>Disseminated information about research findings.

Increased international research profile.</gtr:impact><gtr:outcomeId>5464995737bfd1.74469988</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Undergraduate teaching</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7A9889D4-67C8-454D-A437-1007259447B1</gtr:id><gtr:impact>Co-ordination of final year undergraduate Immunology course at Glasgow University, plus presentations on immunology and cancer/inflammation to ~80 third and fourth year undergraduate students every year. Dissemination of own research findings presented in the broader context of the field.

Education of local young people. Each year 10-12 Immunology graduates undertake PhD studies, with others entering Masters studies or other courses (Medicine, Dentistry, Vet Medicine).</gtr:impact><gtr:outcomeId>dsHKwGErdGH</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Primary School Science Fair (2012)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D7A99F5B-B6CB-4D24-B145-32BAFE873CBD</gtr:id><gtr:impact>100 primary school children and their parents attended a science fair entitled 'Science Rocks' at which I ran an interactive workshop on the history and mechanisms of vaccination.

Feedback was excellent and further 'Science Rocks' events are planned in the local area.</gtr:impact><gtr:outcomeId>NLs6rXqAMkK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>WoS Cancer 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5DFD7F79-EF76-49C7-8AF2-F92A2E7E121D</gtr:id><gtr:impact>Stimulated discussions and collaborative links.

Dissemination of research findings and increased local collaborations.</gtr:impact><gtr:outcomeId>546499c4489265.93710312</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AA57578A-9D25-4D0C-B04C-8968FA9E9F86</gtr:id><gtr:title>Characterization of conventional and atypical receptors for the chemokine CCL2 on mouse leukocytes.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea9c4de01f2e83219464ff6b6da38de9"><gtr:id>ea9c4de01f2e83219464ff6b6da38de9</gtr:id><gtr:otherNames>Ford LB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5464810ac297e5.01517305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CAD5702-3715-44E2-8233-901425EA311C</gtr:id><gtr:title>Atypical chemokine receptor ACKR2 mediates chemokine scavenging by primary human trophoblasts and can regulate fetal growth, placental structure, and neonatal mortality in mice.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4eef6426f9dbf1ffeb4bd3b5c4b5a7ff"><gtr:id>4eef6426f9dbf1ffeb4bd3b5c4b5a7ff</gtr:id><gtr:otherNames>Teoh PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5464810b4bec77.60658856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79516204-5A95-4FCF-B972-A758E3C3A179</gtr:id><gtr:title>Immune checkpoint inhibitors: new strategies to checkmate cancer.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef966bd6e443e901ba1b4416acc62aa7"><gtr:id>ef966bd6e443e901ba1b4416acc62aa7</gtr:id><gtr:otherNames>Wilson RAM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>5aa94e673229a2.76666011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18BC99D6-694B-4CB7-827B-9839611146C7</gtr:id><gtr:title>CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf709a1cd8076eb0fb6bede89fd3e365"><gtr:id>cf709a1cd8076eb0fb6bede89fd3e365</gtr:id><gtr:otherNames>Steele CW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>58b94e3f090562.68736371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22F047D5-2DFE-4F69-94EA-AC2C70734C44</gtr:id><gtr:title>Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24b9c08d8e7240b7ae5713c774821124"><gtr:id>24b9c08d8e7240b7ae5713c774821124</gtr:id><gtr:otherNames>Serrels A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>56dd81a8215b52.14966594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>086BFFAA-CF9A-4C7C-8D12-39C6BF2E1EE3</gtr:id><gtr:title>Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9acc82aece6ad81dee275310756598a7"><gtr:id>9acc82aece6ad81dee275310756598a7</gtr:id><gtr:otherNames>Jamieson T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>pm_15502_22_22922255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E3C8B4E-5827-4D8F-ACD2-0958E55F03CA</gtr:id><gtr:title>CXCR2 inhibition suppresses acute and chronic pancreatic inflammation.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf709a1cd8076eb0fb6bede89fd3e365"><gtr:id>cf709a1cd8076eb0fb6bede89fd3e365</gtr:id><gtr:otherNames>Steele CW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>56dd81a850e7a6.68718190</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900992</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>